Literature DB >> 10644382

Antiplatelet use in interventional cardiology.

A Brodison1, R Katira, R S More, A Chauhan.   

Abstract

Thrombosis within the target vessel is one of the most feared complications associated with coronary intervention, as it is often associated with severe adverse clinical sequelae. This thrombosis is mediated via the activation and aggregation of platelets and therefore considerable effort has been directed at ways of inhibiting platelet function. It is now mandatory to consider the use of two and often three different antiplatelet agents, particularly when intracoronary stents are inserted. Using these regimes, many of the adverse clinical outcomes associated with platelet activation can be reduced.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10644382      PMCID: PMC1741488          DOI: 10.1136/pmj.76.892.70

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  35 in total

1.  Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.

Authors:  E J Topol; J J Ferguson; H F Weisman; J E Tcheng; S G Ellis; N S Kleiman; R J Ivanhoe; A L Wang; D P Miller; K M Anderson; R M Califf
Journal:  JAMA       Date:  1997-08-13       Impact factor: 56.272

2.  Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial.

Authors:  S P Schulman; P J Goldschmidt-Clermont; E J Topol; R M Califf; F I Navetta; J T Willerson; N C Chandra; A D Guerci; J J Ferguson; R A Harrington; A M Lincoff; S J Yakubov; P F Bray; R D Bahr; C L Wolfe; P G Yock; H V Anderson; T W Nygaard; S J Mason; M B Effron; A Fatterpacker; S Raskin; J Smith; L Brashears; P Gottdiener; C du Mee; M M Kitt; G Gerstenblith
Journal:  Circulation       Date:  1996-11-01       Impact factor: 29.690

3.  Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease.

Authors:  D F Kong; R M Califf; D P Miller; D J Moliterno; H D White; R A Harrington; J E Tcheng; A M Lincoff; V Hasselblad; E J Topol
Journal:  Circulation       Date:  1998 Dec 22-29       Impact factor: 29.690

4.  Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review.

Authors:  W D Weaver; R J Simes; A Betriu; C L Grines; F Zijlstra; E Garcia; L Grinfeld; R J Gibbons; E E Ribeiro; M A DeWood; F Ribichini
Journal:  JAMA       Date:  1997-12-17       Impact factor: 56.272

Review 5.  The anti-GPIIb-IIIa agents: fundamental and clinical aspects.

Authors:  B S Coller; K M Anderson; H F Weisman
Journal:  Haemostasis       Date:  1996-10

6.  Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

Authors:  S J Brener; L A Barr; J E Burchenal; S Katz; B S George; A A Jones; E D Cohen; P C Gainey; H J White; H B Cheek; J W Moses; D J Moliterno; M B Effron; E J Topol
Journal:  Circulation       Date:  1998-08-25       Impact factor: 29.690

7.  A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

Authors:  M B Leon; D S Baim; J J Popma; P C Gordon; D E Cutlip; K K Ho; A Giambartolomei; D J Diver; D M Lasorda; D O Williams; S J Pocock; R E Kuntz
Journal:  N Engl J Med       Date:  1998-12-03       Impact factor: 91.245

8.  A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators.

Authors:  D L Fischman; M B Leon; D S Baim; R A Schatz; M P Savage; I Penn; K Detre; L Veltri; D Ricci; M Nobuyoshi
Journal:  N Engl J Med       Date:  1994-08-25       Impact factor: 91.245

9.  Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study.

Authors:  R A Schatz; D S Baim; M Leon; S G Ellis; S Goldberg; J W Hirshfeld; M W Cleman; H S Cabin; C Walker; J Stagg
Journal:  Circulation       Date:  1991-01       Impact factor: 29.690

10.  A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.

Authors:  A Schömig; F J Neumann; A Kastrati; H Schühlen; R Blasini; M Hadamitzky; H Walter; E M Zitzmann-Roth; G Richardt; E Alt; C Schmitt; K Ulm
Journal:  N Engl J Med       Date:  1996-04-25       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.